Maintenance therapy in CTCL

1 Views
administrator
administrator
08/09/23

Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, talks on the benefits of administering maintenance therapy in the management of cutaneous T-cell lymphoma (CTCL), highlighting how high tumor burden means that complete remission rates are low, and commenting on the use of agents such as bexarotene and interferons. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next